Skip to main content
Clinical Trials/NCT06456294
NCT06456294
Active, not recruiting
Not Applicable

Evaluation of a Medication Health Center to Promote Opioid Safety

Kaiser Permanente1 site in 1 country14 target enrollmentStarted: June 15, 2022Last updated:
ConditionsOverdose

Overview

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
14
Locations
1
Primary Endpoint
Number of participants with a Medication Health Center visit

Overview

Brief Summary

This study will assess the impact of an opioid safety clinic intervention for patients prescribed chronic opioid therapy. Outcomes are visits to the clinic, naloxone dispensings, Prescription Drug Monitoring reviews, and Urine Drug Screens conducted

Detailed Description

Given ongoing concerns about the risk of opioid overdose among people taking chronic opioid therapy for pain, Kaiser Permanente Colorado (KPCO) sought to develop a standardized approach to promote opioid safety. Operational stakeholders adapted an existing Opioid Safety Clinic model, tailored it for KPCO's context, and implemented it in three geographically dispersed KPCO clinics with leadership support. The approach was a multidisciplinary "Medication Health Center" to assess patients, educate them about overdose risk, provide naloxone, and ensure adherence to standard monitoring. Operations and the research team then collaborated to assess the effectiveness of the program to inform decisions to scale the program to other regions.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Number of participants with a Medication Health Center visit

Time Frame: Outcomes are assessed in a two-month post-intervention period.

Medication Health Center (MHC) Visits will be assessed using data from the electronic medical record.

Secondary Outcomes

  • Number of participants with a Urine Drug Screens completed(Outcomes are assessed in a two-month post-intervention period.)
  • Number of participants with a Naloxone dispensing(Outcomes are assessed in a two-month post-intervention period.)
  • Number of participants with a Prescription Drug Monitoring Program (PDMP) review(Outcomes are assessed in a two-month post-intervention period.)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials